Andrew Krivoshik, MD of @AstellasUS explains insights on EV-103 enfortumab vedotin plus pembrolizumab that was presented at ESMO.
#ESMO2019
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
Andrew Krivoshik, MD of @AstellasUS explains insights on EV-103 enfortumab vedotin plus pembrolizumab that was presented at ESMO.
#ESMO2019